Boston Scientific Corporation

NYSE:BSX Stock Report

Market Cap: US$111.1b

Boston Scientific Valuation

Is BSX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BSX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: BSX ($77.56) is trading above our estimate of fair value ($72.12)

Significantly Below Fair Value: BSX is trading above our estimate of fair value.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for BSX?

Other financial metrics that can be useful for relative valuation.

BSX key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue8.2x
Enterprise Value/EBITDA32.1x
PEG Ratio3.6x

Price to Earnings Ratio vs Peers

How does BSX's PE Ratio compare to its peers?

The above table shows the PE ratio for BSX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average43.9x
SYK Stryker
38.6x10.5%US$126.2b
MDT Medtronic
27.7x12.9%US$104.1b
ISRG Intuitive Surgical
77.1x11.3%US$161.4b
ABT Abbott Laboratories
32.1x12.0%US$174.1b
BSX Boston Scientific
64.6x18.1%US$111.1b

Price-To-Earnings vs Peers: BSX is expensive based on its Price-To-Earnings Ratio (64.6x) compared to the peer average (43.9x).


Price to Earnings Ratio vs Industry

How does BSX's PE Ratio compare vs other companies in the US Medical Equipment Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a16.8%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a16.8%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: BSX is expensive based on its Price-To-Earnings Ratio (64.6x) compared to the US Medical Equipment industry average (38.6x).


Price to Earnings Ratio vs Fair Ratio

What is BSX's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BSX PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio64.6x
Fair PE Ratio41.5x

Price-To-Earnings vs Fair Ratio: BSX is expensive based on its Price-To-Earnings Ratio (64.6x) compared to the estimated Fair Price-To-Earnings Ratio (41.5x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst BSX forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$77.56
US$84.10
+8.4%
7.0%US$100.00US$70.00n/a31
Jul ’25US$76.41
US$82.35
+7.8%
6.3%US$90.00US$70.00n/a31
Jun ’25US$75.57
US$82.06
+8.6%
6.1%US$90.00US$70.00n/a31
May ’25US$72.21
US$80.80
+11.9%
5.7%US$90.00US$70.00n/a32
Apr ’25US$68.10
US$71.73
+5.3%
5.8%US$81.00US$61.00n/a31
Mar ’25US$67.13
US$71.29
+6.2%
6.6%US$81.00US$55.00n/a30
Feb ’25US$64.82
US$69.67
+7.5%
7.5%US$81.00US$55.00n/a30
Jan ’25US$57.81
US$61.62
+6.6%
7.1%US$77.00US$52.50n/a30
Dec ’24US$56.14
US$60.12
+7.1%
4.9%US$67.00US$52.50n/a30
Nov ’24US$51.66
US$59.98
+16.1%
4.8%US$67.00US$52.50n/a30
Oct ’24US$52.80
US$60.80
+15.1%
4.5%US$66.00US$55.00n/a30
Sep ’24US$53.62
US$59.86
+11.6%
3.9%US$64.00US$55.00n/a30
Aug ’24US$51.89
US$59.61
+14.9%
5.8%US$64.00US$45.00n/a31
Jul ’24US$54.09
US$58.13
+7.5%
5.6%US$64.00US$45.00US$76.4130
Jun ’24US$51.50
US$57.55
+11.7%
5.5%US$62.00US$45.00US$75.5729
May ’24US$52.80
US$56.92
+7.8%
6.3%US$62.00US$45.00US$72.2127
Apr ’24US$50.03
US$52.88
+5.7%
6.2%US$59.00US$45.00US$68.1026
Mar ’24US$46.82
US$52.51
+12.2%
6.3%US$59.00US$45.00US$67.1327
Feb ’24US$47.54
US$51.46
+8.2%
6.0%US$56.00US$45.00US$64.8226
Jan ’24US$46.27
US$49.75
+7.5%
5.9%US$55.00US$45.00US$57.8128
Dec ’23US$46.12
US$48.65
+5.5%
4.4%US$53.00US$45.00US$56.1426
Nov ’23US$42.76
US$48.64
+13.8%
4.9%US$53.00US$45.00US$51.6626
Oct ’23US$38.73
US$48.20
+24.4%
5.6%US$53.00US$43.00US$52.8024
Sep ’23US$40.99
US$48.20
+17.6%
5.6%US$53.00US$43.00US$53.6224
Aug ’23US$41.05
US$47.84
+16.5%
5.5%US$53.00US$43.00US$51.8924
Jul ’23US$38.01
US$48.57
+27.8%
5.9%US$54.00US$43.00US$54.0923

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.